Indeed, CD47 monotherapy has shown preclinical promise in pediatric neuroblastoma models, synergising with GD2-CAR T cell approaches.31 Again, despite preclinical evidence demonstrating efficacy, DMG in the pons is an exclusion criterion in the exploration of anti-CD47 monotherapy in pediatric and adult CNS tumors (NCT05169944). This evidence concerns the gene CD47 and central nervous system neoplasm.